-
Mashup Score: 2Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC - 20 hour(s) ago
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC @fredhutch #crcsm #oncology https://t.co/vsQbA4SCMd
-
-
Mashup Score: 9
Cathy Eng, MD, FACP, FASCO, shares insights on biomarker testing and sequencing strategies for patients with colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC @CathyEngMD @VUMC_Cancer #crcsm #oncology https://t.co/azDmDavBCY
-
-
Mashup Score: 5The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality - 18 day(s) ago
One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality @ae_cancercenter #crcsm #oncology https://t.co/IbysypAkj0
-
-
Mashup Score: 5The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality - 20 day(s) ago
One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality @ae_cancercenter #crcsm #oncology https://t.co/IbysypAkj0
-
-
Mashup Score: 3
GRANITE-based maintenance therapy improved PFS in first-line MSS colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
GRANITE Plus ICIs and Bevacizumab/Chemo Shows Improved PFS Trend in MSS mCRC #crcsm #oncology https://t.co/POy7ySnCkP
-
-
Mashup Score: 3The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality - 29 day(s) ago
One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality @ae_cancercenter #crcsm #oncology https://t.co/IbysypAkj0
-
-
Mashup Score: 3
GRANITE-based maintenance therapy improved PFS in first-line MSS colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
GRANITE Plus ICIs and Bevacizumab/Chemo Shows Improved PFS Trend in MSS mCRC #crcsm #oncology https://t.co/POy7ySnCkP
-
-
Mashup Score: 9
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC #crcsm #oncology https://t.co/qDTEDkzCDb
-
-
Mashup Score: 9
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC #crcsm #oncology https://t.co/qDTEDkzCDb
-
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC #crcsm #oncology https://t.co/Yy9yx86mxv